頁籤選單縮合
題 名 | 從歷年藥害救濟申請案例探討Allopurinol之使用=Clinical Use Pattern of Allopurinol from Drug Hazard Relief Application Cases in Taiwan |
---|---|
作 者 | 遲蘭慧; 翁菀菲; 顏秀瓊; | 書刊名 | 藥學雜誌 |
卷 期 | 27:3=108 2011.09[民100.09] |
頁 次 | 頁113-120 |
分類號 | 418.2133 |
關鍵詞 | 高尿酸血症; 痛風; 藥害救濟; Allopurinol; |
語 文 | 中文(Chinese) |
中文摘要 | 台灣地區高盛行率之痛風及高尿酸血症已是目前基層醫療中常見的問題。高尿酸血症與心血管疾病之潛在關係極須重視,但對於慢性痛風患者與初期或無症狀之高尿酸血症之治療原則應有所區別。藉由歷年藥害救濟審議案件結果,疑似因使用 allopurinol藥物導致藥害之案件數已躍升至首位,顯示該藥物之特性或使用習慣在台灣地區造成藥害發生原因有密切相關。故本研究將針對該藥疑似導致不良反應而申請藥害救濟案例加以分析及整理,以瞭解國人 allopurinol使用情形及不良反應之型態。 |
英文摘要 | High prevalence of gout and hyperuricemia is the currently common problem seen in the primary care in Taiwan. Some researchers believe that hyperureicemia is a risk factor for cardiovascular disease and may be associated with other metabolic disorders, such as diabetes mellitus, serum lipid abnormalities, etc. Treatment for asyptomatic hyperuricemia and chronic gout must depend on pathogenesis and stage of the disease. In the past decades, allopurinol has become the number one medication attributed to the Drug Relief Payment for severe adverse drug reactions (ADRs) in Taiwan. In this article, we analyzed and reported the serious cases of allopuinol Hazard Relief Application in order to understand the prescription patterns and ADRs of allopurinol use in Taiwan, thus to avoid further preventable miseries. |
本系統中英文摘要資訊取自各篇刊載內容。